Gide has advised Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. (the "underwriters") on the initial public offering of Valneva on the Nasdaq Global Select Market, through a capital increase reserved to a category of investors, for an estimated total gross amount of USD 107.6 million, after full exercise of the over-allotment clause.
Valneva is a specialty vaccine company focused on the development and commercialisation of prophylactic vaccines for infectious diseases with significant unmet medical need, including Lyme disease, the Chikungunya virus, and Covid-19.
Gide has been involved in 7 of the last 9 Nasdaq listings of French companies since 2014.
Gide advised the underwriters on French law aspects, with a team headed by partner Arnaud Duhamel and counsel Guilhem Richard, working with associates Mariléna Gryparis and Mélanie Simon. The tax aspects were handled by counsel Alexandre Bochu. The underwriters were advised by Goodwin Protecter on US law aspects.
Valneva was represented by Cooley LLP on aspects of US law and by Hogan Lovells on aspects of French law.